TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31237313

Group type: EXPERIMENTAL
Intervention: Baseline serum 25-hydroxyvitamin D (25(OH)D)
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Baseline serum 1,25-dihydroxyvitamin D (1,25(OH)2D)
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Baseline serum 25(OH)D and 1,25(OH)2D
Number of subjects: 574
Study: 28369940

Group type: EXPERIMENTAL
Intervention: IRS1 rs1801123 C/- carriers (N=105)
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: IGF1 rs2946834 T/- variant (N=280)
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: IGF1 rs2946834 T/- carriers in RAS wild-type subgroup
Number of subjects: 1106
Study: 26178500

Group type: EXPERIMENTAL
Intervention: Propofol (1 mg/kg for induction, maintenance 0.5 mg/kg/h)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Right beauty pyrimidine (1 mg/kg/h for 20 min, maintenance 0.3-0.7 mg/kg/h)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 72
Study: 23465819

Group type: EXPERIMENTAL
Intervention: IUD insertion
Number of subjects: 120
Study: 21135266

Group type: EXPERIMENTAL
Intervention: Daily sunscreen application
Number of subjects: 1621

Group type: COMPARATOR
Intervention: Discretionary sunscreen application
Number of subjects: 1621
Study: 19860981

Group type: EXPERIMENTAL
Intervention: Biological specimen collection (blood and urine)
Number of subjects: 85
Study: 16850001

Group type: EXPERIMENTAL
Intervention: Active dissemination of CPGs (multifaceted educational interventions including Web-based tools to dietitians)
Number of subjects: 623

Group type: COMPARATOR
Intervention: Passive dissemination of CPGs (mailed guidelines to dietitians)
Number of subjects: 623
Study: 10874266

Group type: EXPERIMENTAL
Intervention: Prophylactic abciximab
Number of subjects: 178

Group type: COMPARATOR
Intervention: Prophylactic placebo
Number of subjects: 178
Study: 8931526

Group type: EXPERIMENTAL
Intervention: Thermal coagulation of the tibial nerve
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Polypropylene ankle-foot orthosis
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both treatments combined
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Comfortable and maximal safe walking speed
Number of subjects: 60
Study: 1383520

Group type: EXPERIMENTAL
Intervention: Oral fluid only
Number of subjects: 93

Group type: COMPARATOR
Intervention: Intravenous fluids
Number of subjects: 93
Study: 3890764

Group type: EXPERIMENTAL
Intervention: Bedtime insulin injections
Number of subjects: 16

Group type: COMPARATOR
Intervention: Teatime insulin injections
Number of subjects: 16
Study: 3542981

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 90

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 90
Study: 28982804

Group type: EXPERIMENTAL
Intervention: autoCPAP (5‐15 mbar)
Number of subjects: 208

Group type: COMPARATOR
Intervention: fCPAP (pressure set at the 90th percentile applied by autoCPAP during 2‐4 weeks adaptation)
Number of subjects: 208
Study: 28847546

Group type: EXPERIMENTAL
Intervention: mAF App
Number of subjects: 209
Study: 25704221

Group type: EXPERIMENTAL
Intervention: Functional restoration program with forward head posture corrective exercises
Number of subjects: 154

Group type: COMPARATOR
Intervention: Functional restoration program without forward head posture corrective exercises
Number of subjects: 154
Study: 23838604

Group type: EXPERIMENTAL
Intervention: ACE inhibitor-associated angioedema
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: T allele of rs500766 in PRKCQ
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: G allele of rs2724635 in ETV6
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: rs989692 in the gene encoding neprilysin (MME)
Number of subjects: 664
Study: 21947196

Group type: EXPERIMENTAL
Intervention: Anakinra (IL-1 receptor antagonist)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 46
Study: 18431084

Group type: EXPERIMENTAL
Intervention: Physical training program (aerobic, muscle strength, balance)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Nutritional intervention program (individually targeted advice and group sessions)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Combination of physical training and nutritional intervention
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study: 16926660

Group type: EXPERIMENTAL
Intervention: Dietary counselling (and placebo)
Number of subjects: 563

Group type: COMPARATOR
Intervention: Control (no dietary counselling and placebo)
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA supplementation (no dietary counselling)
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Dietary counselling and omega-3 PUFA supplementation
Number of subjects: 563
Study: 12675646

Group type: EXPERIMENTAL
Intervention: Insulin aspart with intensified basal NPH insulin supplementation
Number of subjects: 368

Group type: COMPARATOR
Intervention: Human regular insulin with standard basal NPH insulin
Number of subjects: 368
Study: 11123453

Group type: EXPERIMENTAL
Intervention: Psoralen-ultraviolet A (PUVA) therapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Psoralen-ultraviolet B (PUVB) therapy
Number of subjects: 44
Study: 9177984

Group type: EXPERIMENTAL
Intervention: Ambroxol treatment (group A)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control (group B)
Number of subjects: 88
Study: 1545249

Group type: EXPERIMENTAL
Intervention: AT877 (30 mg, intravenous injection over 30 minutes, three times a day for 14 days)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo (saline, intravenous injection over 30 minutes, three times a day for 14 days)
Number of subjects: 267
Study: 3893805

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 29254398

Group type: EXPERIMENTAL
Intervention: Latin dance program
Number of subjects: 21

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 21
Study: 28634654

Group type: COMPARATOR
Intervention: guselkumab treatment
Number of subjects: 238
Study: 26450000

Group type: EXPERIMENTAL
Intervention: Pump design modifications and protocol-driven change in antiplatelet therapy
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Improved blood pressure management (IBPM) protocols
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Aspirin ≤81 mg and atrial fibrillation
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Mean arterial pressure >90 mm Hg, aspirin ≤81 mg, and international normalized ratio >3.0
Number of subjects: 382
Study: 24119597

Group type: EXPERIMENTAL
Intervention: Bilateral maxillary sinus saline irrigation for 2 months after ESS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no irrigation)
Number of subjects: 30
Study: 20465357

Group type: EXPERIMENTAL
Intervention: Intravenous cortisol infusion before retrieval testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19552867

Group type: EXPERIMENTAL
Intervention: Duloxetine 60‐120 mg once daily
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study: 17377086

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg + Ondansetron 4 mg (Group D4/O4)
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg + Ondansetron 2 mg (Group D4/O2)
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Dexamethasone 2 mg + Ondansetron 4 mg (Group D2/O4)
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Dexamethasone 2 mg + Ondansetron 2 mg (Group D2/O2)
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: All groups (D4/O4, D4/O2, D2/O4, D2/O2)
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Dexamethasone 2 mg (Groups D2/O4 and D2/O2)
Number of subjects: 614
Study: 15000732

Group type: EXPERIMENTAL
Intervention: Benzathine penicillin (1.2 million units as a single dose)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Metronidazole (600 mg every 6 h for 10 days)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Benzyl penicillin (2 million units every 4 h for 10 days)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Benzathine penicillin
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Benzyl penicillin
Number of subjects: 161
Study: 11772897

Group type: EXPERIMENTAL
Intervention: Group-based stress management training
Number of subjects: 108
Study: 9665189

Group type: EXPERIMENTAL
Intervention: High-dose AraC (3.0 g/m2 for patients younger than 60 years; 1.0 g/m2 for older patients)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Intermediate-dose AraC (1.0 g/m2 for patients younger than 60 years; 0.5 g/m2 for older patients)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: High-dose AraC in refractory AML subgroup
Number of subjects: 186

Group type: COMPARATOR
Intervention: Intermediate-dose AraC in older patients
Number of subjects: 186
Study: 8555377

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FXT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) breakfast
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Protein-rich (PROT) breakfast
Number of subjects: 34
Study: 2713622

Group type: EXPERIMENTAL
Intervention: Transurethral siliconised latex catheter
Number of subjects: 205

Group type: COMPARATOR
Intervention: Suprapubic siliconised latex catheter
Number of subjects: 205
Study: 709793

Group type: EXPERIMENTAL
Intervention: Powder administration of beclomethasone dipropionate (100 micrograms, 4 doses)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Aerosol administration of beclomethasone dipropionate (100 micrograms, 4 doses)
Number of subjects: 37
Study: 31957152

Group type: EXPERIMENTAL
Intervention: Topical minoxidil 5%
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Topical minoxidil 2%
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Oral finasteride 1 mg daily
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control lotion (1 mL/d)
Number of subjects: 22
Study: 30404088

Group type: EXPERIMENTAL
Intervention: SUTMEK-milk
Number of subjects: 15

Group type: COMPARATOR
Intervention: SUTMEK-placebo
Number of subjects: 15

Group type: COMPARATOR
Intervention: SUTMEK-milk or SUTMEK-placebo
Number of subjects: 15
Study: 28385735

Group type: EXPERIMENTAL
Intervention: Sitting with prior exercise (45 min leg cycling)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sitting without prior exercise
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standing without prior exercise
Number of subjects: 15
Study: 25418979

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23385271

Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg/d for 24 weeks
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 21115010

Group type: EXPERIMENTAL
Intervention: Aspirin/NSAID use after blood collection
Number of subjects: 32826

Group type: COMPARATOR
Intervention: Highest quartile of plasma levels of sTNFR-2
Number of subjects: 32826

Group type: COMPARATOR
Intervention: Plasma levels of CRP and IL-6
Number of subjects: 32826
Study: 19214525

Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study: 17855283

Group type: EXPERIMENTAL
Intervention: Patching for six hours a day
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Patching for twelve hours a day
Number of subjects: 97

Group type: COMPARATOR
Intervention: Patching for less than three hours a day
Number of subjects: 97
Study: 14986556

Group type: EXPERIMENTAL
Intervention: 1 mg intranasal butorphanol (single dose)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2 mg intranasal butorphanol (single dose)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1 mg intranasal butorphanol (multiple doses every six hours for seven doses)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2 mg intranasal butorphanol (multiple doses every six hours for seven doses)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1 mg and 2 mg intranasal butorphanol
Number of subjects: 24

Group type: COMPARATOR
Intervention: 2 mg vs 1 mg intranasal butorphanol (single dose)
Number of subjects: 24
Study: 11687362

Group type: EXPERIMENTAL
Intervention: Capsular tension ring (CTR) implantation
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (no CTR)
Number of subjects: 78
Study: 9270151

Group type: EXPERIMENTAL
Intervention: Paid publicity on ethnic radio during three discrete periods between 1992 and 1994
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (areas with low proportion of women of non-English-speaking background)
Number of subjects: 0
Study: 7870219

Group type: EXPERIMENTAL
Intervention: First-line chemotherapy with cisplatin
Number of subjects: 62

Group type: COMPARATOR
Intervention: Second/third-line chemotherapy with cisplatin
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Bolus CDDP
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Cisplatin-containing regimens
Number of subjects: 62
Study: 3422292

Group type: EXPERIMENTAL
Intervention: Electromagnetic stimulation (EMS) applied for eight weeks post-surgery
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (surgery only)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Electromagnetic stimulation (EMS)
Number of subjects: 23
Study: 29431549

Group type: EXPERIMENTAL
Intervention: Self-paced cycling (15 min daily for 15 months)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Recreational activities (control group)
Number of subjects: 39
Study: 27803064

Group type: EXPERIMENTAL
Intervention: Veliparib (120 mg) with carboplatin and paclitaxel
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo with carboplatin and paclitaxel
Number of subjects: 158
Study: 25673216

Group type: EXPERIMENTAL
Intervention: Monitoring pressure (being watched by the experimenter)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 24144760

Group type: EXPERIMENTAL
Intervention: Alprostadil injection at 10 µg/d for 2 weeks
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Sequential treatment with alprostadil injection at 10 µg/d for 2 weeks and oral beraprost sodium at 20 µg three times a day for 12 weeks
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Strengthened sequential treatment with alprostadil injection at 20 µg/d for 2 weeks and double dose of oral beraprost sodium for 12 weeks
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (conventional treatment)
Number of subjects: 63
Study: 21563879

Group type: EXPERIMENTAL
Intervention: 40 ml × 1 blood culture
Number of subjects: 258

Group type: COMPARATOR
Intervention: 20 ml × 1 blood culture
Number of subjects: 258

Group type: COMPARATOR
Intervention: 20 ml × 2 blood culture
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: MB BacT culture
Number of subjects: 258

Group type: COMPARATOR
Intervention: Isolator culture
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 258
Study: 18440489

Group type: EXPERIMENTAL
Intervention: Ilioinguinal nerve excision
Number of subjects: 121

Group type: COMPARATOR
Intervention: Ilioinguinal nerve preservation
Number of subjects: 121
Study: 16476552

Group type: EXPERIMENTAL
Intervention: Smartcanula (SC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control cannula (CC)
Number of subjects: 30
Study: 12620603

Group type: EXPERIMENTAL
Intervention: Placebo analgesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naloxone (opioid antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol (beta-blocker)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atropine (muscarinic blocker)
Number of subjects: 0
Study: 10994571

Group type: EXPERIMENTAL
Intervention: Drugs specifically prescribed for AD (tacrine, donepezil, and rivastigmine)
Number of subjects: 0
Study: 9093045

Group type: EXPERIMENTAL
Intervention: Follow up by a specially trained nurse (intervention group)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Follow up by general practitioners (usual care group)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Physical training programme (intervention group)
Number of subjects: 168
Study: 8166473

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (specific drugs not detailed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single agent etoposide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of etoposide and cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with hematopoietic growth factors
Number of subjects: 0
Study: 2472242

Group type: EXPERIMENTAL
Intervention: Tocainide 1800 mg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tocainide 1200 mg + Metoprolol 200 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tocainide 1800 mg + Metoprolol 200 mg
Number of subjects: 20
Study: 951471

Group type: EXPERIMENTAL
Intervention: Feedback for increasing alpha activity
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Feedback for suppression of alpha activity
Number of subjects: 36

Group type: COMPARATOR
Intervention: Rest periods without feedback
Number of subjects: 36
Study: 31941707

Group type: EXPERIMENTAL
Intervention: Web-based dietary intervention with text messages
Number of subjects: 50

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 50
Study: 30150004

Group type: EXPERIMENTAL
Intervention: Protein + CHO
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Protein + LEU
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Protein + CHO + LEU
Number of subjects: 20

Group type: COMPARATOR
Intervention: Protein only
Number of subjects: 20
Study: 28613284

Group type: EXPERIMENTAL
Intervention: Activated and micronized zeolites (5.4 g once a day for 30 days)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 mg D‐alpha tocopheryl acetate once a day for 30 days)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Maltodextrin (250 mg once a day for 30 days)
Number of subjects: 85
Study: 25457497

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.5mg once daily
Number of subjects: 82

Group type: COMPARATOR
Intervention: Prednisolone 5mg twice daily
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Intermittent dexamethasone 8mg twice daily on days 1-3 every 3 weeks
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 82

Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Dexamethasone after crossover from prednisolone
Number of subjects: 82
Study: 23104724

Group type: EXPERIMENTAL
Intervention: 10-mg/kg intetumumab
Number of subjects: 131

Group type: COMPARATOR
Intervention: 75-mg/m2 docetaxel + 5-mg prednisone + placebo
Number of subjects: 131
Study: 21977811

Group type: EXPERIMENTAL
Intervention: TCM and Western medicine
Number of subjects: 62

Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 62
Study: 19403231

Group type: EXPERIMENTAL
Intervention: Counting from 1 to 10, repeated three times
Number of subjects: 48

Group type: COMPARATOR
Intervention: Counting from 1 to 30
Number of subjects: 48
Study: 17071254

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 104

Group type: COMPARATOR
Intervention: Nonpropofol (Control)
Number of subjects: 104
Study: 15296559

Group type: EXPERIMENTAL
Intervention: Previous consultations
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: Multilevel models
Number of subjects: 935
Study: 11087152

Group type: EXPERIMENTAL
Intervention: Low/stop corticosteroid regimen (half dosage for 3 months, then withdrawn)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control corticosteroid regimen (standard dosage)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Low/stop corticosteroid regimen
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control corticosteroid regimen
Number of subjects: 500
Study: 8520339

Group type: EXPERIMENTAL
Intervention: Diabetes guidelines
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Asthma guidelines
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Structured consultation prompts
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 24
Study: 1904310

Group type: EXPERIMENTAL
Intervention: CHAP II (hexamethylmelamine dosage‐intensive regimen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CHAP I (hexamethylmelamine regimen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salvage therapy with hexamethylmelamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CHAP I & II (hexamethylmelamine‐containing regimens)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CHAP II
Number of subjects: 0
Study: 6124495

Group type: EXPERIMENTAL
Intervention: i.v. Ranitidine 50 mg b.d. (or oral ranitidine 150 mg b.d. for up to 10 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard conservative therapy
Number of subjects: 50
Study: 30686305

Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 150

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 150
Study: 28552382

Group type: EXPERIMENTAL
Intervention: Icatibant 30 mg
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 25500324

Group type: EXPERIMENTAL
Intervention: Short-acting reversible contraception (SARC)
Number of subjects: 917

Group type: EXPERIMENTAL
Intervention: Long-acting reversible contraception (LARC)
Number of subjects: 917

Group type: COMPARATOR
Intervention: Preference cohort (self-selected method use)
Number of subjects: 917

Group type: COMPARATOR
Intervention: Randomized cohort
Number of subjects: 917
Study: 24177484

Group type: EXPERIMENTAL
Intervention: Family adversity (domestic violence, family substance use, broken parental marriage)
Number of subjects: 5607

Group type: EXPERIMENTAL
Intervention: Decreased family function
Number of subjects: 5607

Group type: EXPERIMENTAL
Intervention: Low level of self-esteem
Number of subjects: 5607
Study: 21433025

Group type: EXPERIMENTAL
Intervention: Pramipexole (0.088 mg t.i.d. in week 1; 0.18 mg t.i.d. in week 2; 0.7 mg t.i.d. in week 3; 0.18 mg t.i.d. for 3 days and 0.088 mg t.i.d. for the rest of week 4)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 40